Roche’s Actemra/RoActemra (tocilizumab) has failed to achieve the primary endpoint in the phase III trial, which included hospitalised patients with severe Covid-19 associated pneumonia.
AstraZeneca said that Farxiga (dapagliflozin) has succeeded in a phase 3 trial in chronic kidney disease (CKD) by meeting all its primary and secondary endpoints.
AI Therapeutics announced the start of Phase II clinical trial for the treatment of newly diagnosed Covid-19 patients in collaboration with Yale University.
NeoImmuneTech announced receipt of IND clearance from the US Federal Drug Administration (FDA) to evaluate NT-I7 (efineptakin alfa), the only clinical-stage long-acting human IL-7, in a Window-of-Opportunity trial for patients with locally recurrent squamous cell carcinoma of head and neck (SCCHN) undergoing salvage surgery.
Pfizer, along with BioNTech, has commenced the phase 2/3 safety and efficacy clinical study to assess a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine programme against SARS-CoV-2.
Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announced that it has obtained authorization to launch its phase IIa clinical trial in COVID-19 patients in France, Belgium and the USA.
Medidata, a Dassault Systèmes company, the global leader in creating end-to-end solutions supporting the entire clinical trial process, announced that it is collaborating with Moderna to support clinical trials of mRNA-1273, Moderna’s COVID-19 vaccine candidate.
Clinical-stage pharmaceutical company Humanetics has secured financing from the National Institute of Allergy and Infectious Diseases (NIAID) to carry out a test with its BIO 300 drug in Covid-19 patients.
Expert system services provide peace of mind and ensure that your analyzer is performing optimally to deliver process control.
XyloCor Therapeutics announced it has successfully dosed the first two patients in the EXACT Trial, a Phase 1/2 dose escalation trial evaluating the safety, tolerability and efficacy of its lead candidate XC001 in patients with refractory angina.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.